Replies to post #145389 on Biotech Values

[ghmm]

BMRN:

Yesterday's price move was likely due to this (GSK rumor) of note is the mention of the word "soon"

http://www.guardian.co.uk/business/marketforceslive/2012/jul/13/glaxosmithkline-drug-approval-biomarin

I still think Shire is the most likely (best fit) though I'd love to see a bidding war (I think Shire may not be the winner if that would be the case).

With PEG-PAL, GALNS, Pompe, PARP data (likely that order) late this year into early next can see will certainly have some important news flow that could affect price if no deal.

I like BMRN long-term though I am not unsypathetic to Dew's post about too many companies getting into rare diseases (Actelion with the latest announcement - though not fan of theirs). So I wouldn't be too upset if they get taken out (at a nice premium).